DRIO Quote, Financials, Valuation and Earnings

National Research has a net margin of -126.67% compared to DarioHealth's net margin of 17.25%. DarioHealth's return on equity of -63.85% beat National Research's return on equity of 70.08%.

DarioHealth has a consensus price target of $2.33, signalling upside risk potential of 223.49%. On the other hand National Research has an analysts' consensus of -- which suggests that it could fall by --. Given that DarioHealth has higher upside potential than National Research, analysts believe DarioHealth is more attractive than National Research.

DarioHealth has a beta of 1.552, which suggesting that the stock is 55.239% more volatile than S&P 500. In comparison National Research has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.395%.

DarioHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research offers a yield of 3.57% to investors and pays a quarterly dividend of $0.12 per share. DarioHealth pays -- of its earnings as a dividend. National Research pays out 46.21% of its earnings as a dividend. National Research's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DarioHealth quarterly revenues are $7.6M, which are smaller than National Research quarterly revenues of $33.6M. DarioHealth's net income of -$9.6M is lower than National Research's net income of $5.8M. Notably, DarioHealth's price-to-earnings ratio is -- while National Research's PE ratio is 13.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth is 1.02x versus 2.24x for National Research. Usually stocks with elevated PS ratios are considered overvalued.

Ontrak has a net margin of -126.67% compared to DarioHealth's net margin of -217.21%. DarioHealth's return on equity of -63.85% beat Ontrak's return on equity of -231.34%.

DarioHealth has a consensus price target of $2.33, signalling upside risk potential of 223.49%. On the other hand Ontrak has an analysts' consensus of $4.00 which suggests that it could grow by 140.96%. Given that DarioHealth has higher upside potential than Ontrak, analysts believe DarioHealth is more attractive than Ontrak.

DarioHealth has a beta of 1.552, which suggesting that the stock is 55.239% more volatile than S&P 500. In comparison Ontrak has a beta of 2.298, suggesting its more volatile than the S&P 500 by 129.787%.

DarioHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ontrak offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth pays -- of its earnings as a dividend. Ontrak pays out -- of its earnings as a dividend.

DarioHealth quarterly revenues are $7.6M, which are larger than Ontrak quarterly revenues of $2.6M. DarioHealth's net income of -$9.6M is lower than Ontrak's net income of -$5.6M. Notably, DarioHealth's price-to-earnings ratio is -- while Ontrak's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth is 1.02x versus 0.71x for Ontrak. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings has a net margin of -126.67% compared to DarioHealth's net margin of 14.32%. DarioHealth's return on equity of -63.85% beat Spok Holdings's return on equity of 10.19%.

DarioHealth has a consensus price target of $2.33, signalling upside risk potential of 223.49%. On the other hand Spok Holdings has an analysts' consensus of $20.00 which suggests that it could grow by 21.88%. Given that DarioHealth has higher upside potential than Spok Holdings, analysts believe DarioHealth is more attractive than Spok Holdings.

DarioHealth has a beta of 1.552, which suggesting that the stock is 55.239% more volatile than S&P 500. In comparison Spok Holdings has a beta of 0.515, suggesting its less volatile than the S&P 500 by 48.497%.

DarioHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings offers a yield of 7.62% to investors and pays a quarterly dividend of $0.31 per share. DarioHealth pays -- of its earnings as a dividend. Spok Holdings pays out 176.29% of its earnings as a dividend.

DarioHealth quarterly revenues are $7.6M, which are smaller than Spok Holdings quarterly revenues of $36.3M. DarioHealth's net income of -$9.6M is lower than Spok Holdings's net income of $5.2M. Notably, DarioHealth's price-to-earnings ratio is -- while Spok Holdings's PE ratio is 21.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth is 1.02x versus 2.43x for Spok Holdings. Usually stocks with elevated PS ratios are considered overvalued.